TGF-β1 increases cellular invasion of colorectal neuroendocrine carcinoma cell line through partial epithelial-mesenchymal transition

Epithelial-mesenchymal transition (EMT) plays a pivotal role in cancer progression and metastasis in many types of malignancies, including colorectal cancer. Although the importance of EMT is also considered in colorectal neuroendocrine carcinoma (NEC), its regulatory mechanisms have not been elucidated. We recently established a human colorectal NEC cell line, SS-2. In this study, we aimed to clarify whether these cells were sensitive to transforming growth factor beta 1 (TGF-beta 1) and whether EMT could be induced through TGF-beta 1/Smad signaling, with the corresponding NEC cell-specific changes in invasiveness. In SS-2 cells, activation of TGF-beta 1 signaling, as indicated by phosphorylation of Smad2/3, was dose-dependent, demonstrating that SS-2 cells were responsive to TGF-beta 1. Analysis of EMT markers showed that mRNA levels changed with TGF-beta 1 treatment and that E-cadherin, an EMT marker, was expressed in cell-cell junctions even after TGF-beta 1 treatment. Invasion assays showed that TGF-beta 1-treated SS-2 cells invaded more rapidly than non-treated cells, and these cells demonstrated increased metalloproteinase activity and cell adhesion. Among integrins involved in cell-to-matrix adhesion, alpha 2-integrin was exclusively upregulated in TGF-beta 1-treated SS-2 cells, but not in other colon cancer cell lines, and adhesion and invasion were inhibited by an anti-alpha 2-integrin blocking antibody. Our findings suggest that alpha 2-integrin may represent a novel therapeutic target for the metastasis of colorectal NEC cells.

Automated summary

Activation of TGF-beta 1/Smad signaling pathway induces EMT and increases invasion in colorectal NEC cells. Alpha 2-integrin may serve as a therapeutic target for the metastasis of colorectal NEC cells.